References
1Johnston, L.D.; O'Malley, P.M.; and Bachman, J.G. Monitoring the Future; National Results on Adolescent Drug Use, Overview and Key findings, 2000. NIH Pub. No. 01-4923. Bethesda, MD: NIDA, NIH, DHHS, 2000.
2Substance Abuse and Mental Health Services Administration. Technical appendices and Selected Data Tables: Results from the 2001 National Household Survey on Drug Abuse. NHSDA Series H-18. DHHS Pub. No. (SMA) 02-3759. Rockville, MD: DHHS, 2002.
3ElSohly, M.A., and Ross, S.A. Quarterly report: Potency monitoring project. November 2002, unpublished.
4Tashkin, D.P. Pulmonary complications of smoked substance abuse. West J Med 152:525-530, 1990.
5Sarafian, T.A.; Magallanes, J.A.; Shau, H.; Tashkin, D.; and Roth, M.D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol 20(6):1286-1293, 1999.
6Roth, M.D.; Arora, A.; Barsky, S.H.; Kleerup, E.C.; Simmons, M.; and Tashkin, D.P. Airway inflammation in young marijuana and tobacco smokers. Am. J. Respir Crit Care Med 157:928-937, 1998.
7Heishman, S.J.; Arasteh, K; and Stitzer, M.L. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav 58:97-101, 1997.
8Fletcher, J.M.; Page, J.B.; Francis, D.J.; Copeland, K.; Naus, M.J.; Davis, C.M.; Morris, R.; Krauskopf, D.; and Santz, P. Cognitive correlates of chronic cannabis use in Costa Rican men. Archives of General Psychiatry 53:1051-1057, 1996.
9Block, R.I., and Ghoneim, M.M. Effects of chronic marijuana use on human cognition. Psychopharmacology 100(1-2): 219-228, 1993.
10Graham, A.W.; Schultz, T.K.; and Wilford, B.B. (eds.). Principles of Addiction Medicine, 2nd Edition. Chevy Chase, MD: American Society of Addiction Medicine, Inc., 1998.
11Ameri, A. The effects of cannabinoids on the brain. Prog Neurobiol 58(4):315-348, 1999.
12Patrick, G., and Struve, F.A. Reduction of auditory P50 gating response in marihuana users: further supporting data. Clin Electroencephalogr 31(2):88-93, 2000.
13Jones, R.T., et al. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21(8-9 Suppl):143S-152S, 1981.
14Srivistava, M.D.; Srivastava, B.I.; and Brouhard, B. Delta-9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40(3):179-185, 1998.
15Zhu, L.X.; Stolina, M.; Sharma, S.; Gardner, B.; Roth, M.D.; Tashkin, D.P.; and Dubinett, S.M. Delta-9 tetrahydrocannabinol inhibits antitumor immunity by a CB-2 receptor-mediated, cytokine dependent-pathway. J Immunology 165(1):373-380, 2000.
16Gilman, A.G.; Rall, T.W.; Nies, A.S.; and Taylor, P. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Edition. New York: Pergamon Press, 1998.
17Adams, I.B., and Martin, B.R. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 91:1585-1614, 1996.
18Zhang, Z.-F.; Morgenstern, H.; Spitz, M.R.; Tashkin, D.P.; Yu, G.-P.; Marshall, J.R.; Hsu, T.C; and Stimson, P.S. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiology, Biomarkers & Prevention 6:1071-1078, 1999.
19Brook, J.S., et al. The effect of early marijuana use on later anxiety and depressive symptoms. NYS Psychologist January:35-39, 2001.
20Green, B.E., and Ritter, C. Marijuana use and depression. J Health Soc Behav 41(1):40-49, 2000.
21Wilson, W.; Mathew, R.; Turkington, T.; Hawk, T.; Coleman, R.E.; and Provenzale, J. Brain morphological changes and early marijuana use: A magnetic resonance and positron emission tomography study. J Addict Dis 19(1):1-22, 2000.
22Brook, J.S.; Balka, E.B.; and Whiteman, M. The risks for late adolescence of early adolescent marijuana use. Am J Public Health 89(10):1549-1554, 1999.
23Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse, June 2000. Vol. 1, Highlights and Executive Summary. NIH Pub. No. 00-4739A. Bethesda, MD: NIDA, NIH, DHHS, 2000.
24ElSohly, M.A.; Ross, S.A.; Mehmedic, Z.; Arafat, R.; Yi, B.; and Banahan, B. Potency trends of delta-9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of Forensic Sciences 45(1):24-30, 2000.
25Office of Applied Studies. Results from the 2001 National Household Survey on Drug Abuse: Volume II. Technical Appendices and Selected Data Tables. NHSDA Series H-18. DHHS Pub. No. (SMA) 02-3759. Rockville, MD: SAMHSA, 2002.
26Johnston, L.D.; O'Malley, P.M.; and Bachman, J.G. Monitoring the Future: National Survey Results on Drug Use, 1975-2001. Volume I: Secondary School Students. NIH Pub. No. 02-5106. Bethesda, MD: NIDA, NIH, DHHS, 2002.
27Office of Applied Studies. Year-end 2000 Emergency Department Data from the Drug Abuse Warning Network (Table 24). DAWN Series D-18; DHHS Pub. No. (SMA) 01-3532. Rockville, MD: SAMHSA, 2001.
28National Institute of Justice, Arrestee Drug Abuse Monitoring Program. 1999 Annual Report on Drug Use Among Adult and Juvenile Arrestees. Washington, DC: U.S. Department of Justice, June 2000.
29Herkenham, M.; Lynn, A.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; and Rice K.C. Cannabinoid receptor localization in the brain. Proc Natl Acad Sci, USA. 87:1932-1936, 1990.
30Ohlsson, A.; Lindgren, J.E.; Wahlen, A.; Agurell, S.; Hollister, L.E.; and Gillespie, H.K. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28(3):409-416, 1980.
31Foltin, R.W.; Fischman, M.W; Pedroso, J.J.; and Pearlson, G.D. Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav 28(4):459-464,1987.
32Chen, J.P.; Paredes, W.; Li, J.; Smith, D.; Lowinson, J.; and Gardner, E.L. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156-162, 1990.
33French, E.D.; Dillon, K.; and Wu, X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neurosci Lett 226:159-162, 1997.
34Leshner, A.I., and Koob, G.F. Drugs of abuse and the brain. Proc Assoc Amer Physicians 111:99-108, 1999.
35Pope, H.G., and Yurgelun-Todd, D. The residual cognitive effects of heavy marijuana use in college students. JAMA 272(7):521-527, 1996.
36Mason, A.P., and McBay, A.J. Ethanol, marijuana, and other drug use in 600 drivers killed in single-vehicle crashes in North Carolina, 1978Ð1981. J Forensic Sci 29(4):987-1026, 1984.
37Williams, A.F.; Peat, M.A.; Crouch, D.J.; Wells, J.K.; and Finkle, B.S. Drugs in fatally injured young male drivers. Public Health Report 100:19-25, 1985.
38Cimbura, G.; Lucas, D.M.; Bennett, R.C.; and Donelson, A.C. Incidence and toxicological aspects of cannabis and ethanol detected in 1,394 fatally injured drivers and pedestrians in Ontario (1982Ð1984). J Forensic Sci 35:1035-1041, 1990.
39National Highway Traffic Safety Administration (NHSTA) Notes. Marijuana and alcohol combined severely impede driving performance. Annals of Emergency Medicine 35(4):398-399, 2000.
40Ford, D.E.; Vu, H.T.; and Anthony, J.C. Marijuana use and cessation of tobacco smoking in adults from a community sample. Drug and Alcohol Dependence 67:243-248, 2002.
41Polen, M.R; Sidney, S.; Tekawa, I.S.; Sadler. M.; and Friedman, G.D. Health care use by frequent marijuana smokers who do not smoke tobacco. West J Med 158:596-601, 1993.
42Sridhar, K.S.; Raub, W.A.; Weatherby, N.L., Jr.; Metsch, L.R.; Surratt, H.L.; Inciardi, J.A.; Duncan, R.C.; Anwyl, R.S.; and McCoy, C.B. Possible role of marijuana smoking as a carcinogen in the development of lung cancer at a young age. Journal of Psychoactive Drugs 26(3):285-288, 1994.
43Hoffman, D.; Brunnemann, K.D.; Gori, G.B.; and Wynder, E.E.L. On the carcinogenicity of marijuana smoke. In: V.C. Runeckles, ed., Recent Advances in Phytochemistry. New York: Plenum, 1975.
44Cohen, S. Adverse effects of marijuana: Selected issues. Annals of the New York Academy of Sciences 362:119-124, 1981.
45Klein, T.W.; Newton, C.; and Friedman, H. Resistance to Legionella pneumophila suppressed by the marijuana component, tetrahydrocannabinol. Journal of Infectious Disease 169:1177-1179, 1994.
46Mittleman, M.A.; Lewis, R.A.; Maclure, M.; Sherwood, J.B.; and Muller, J.E. Triggering myocardial infarction by marijuana. Circulation 103:2805-2809, 2001.
47Lynskey. M., and Hall, W. The effects of adolescent cannabis use on educational attainment: A review. Addiction 95(11):1621-1630, 2000.
48Kandel, D.B., and Davies, M. High school students who use crack and other drugs. Arch Gen Psychiatry 53(1):71-80, 1996.
49Rob, M.; Reynolds, I.; and Finlayson, P.F. Adolescent marijuana use: Risk factors and implications. Aust NZ J Psychiatry 24(1):45-56, 1990.
50Lehman, W.E., and Simpson, D.D. Employee substance abuse and on-the-job behaviors. Journal of Applied Psychology 77(3):309-321, 1992.
51Brook, J.S.; Cohen, P.; and Brook, D.W. Longitudinal study of co-occurring psychiatric disorders and substance use. J Acad Child and Adolescent Psych 37:322-330, 1998.
52Pope, H.G.; and Gruber, A.J.; Hudson, J.I.; Huestis, M.A.; and Yurgelun-Todd. D. Neuropsychological performance in long-term cannabis users. Archives of General Psychiatry. Arch Gen Psychiatry 58(10):909-915, 2001.
53Scheier, L.M., and Botvin, G.J. Effects of early adolescent drug use on cognitive efficacy in early-late adolescence: A developmental structural model. Journal of Substance Abuse 7(4):397-404, 1996.
54Lester, B.M., and Dreher, M. Effects of marijuana use during pregnancy on newborn cry. Child Development 60:764-771, 1989.
55Fried, P.A. The Ottawa prenatal prospective study (OPPS): Methodological issues and findingsÑit's easy to throw the baby out with the bath water. Life Sciences 56:2159-2168, 1995.
56Fried, P.A. Prenatal exposure to marihuana and tobacco during infancy, early and middle childhood: Effects and an attempt at synthesis. Arch Toxicol Suppl 17:233-60, 1995.
57Office of Applied Studies. National and State Estimates of the Drug Abuse Treatment Gap: 2000 National Household Survey on Drug Abuse. NHSDA Series H-14. DHHS Pub. No. (SMA) 02-3640. Rockville, MD: SAMHSA, 2002.
58Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS): 1994-1999, National Admissions to Substance abuse Treatment Services. DASIS Series: S-14, DHHS Pub. No. (SMA) 01-3550. Rockville, MD: DHHS, 2001.
59Haney, M.; Ward, A.S.; Comer, S.D.; Foltin, R.W.; and Fischman, M.W. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395-404, 1999.
60Budney, A.J.; Hughes, J.R.; Moore, B.A.; and Novy, P.L. Marijuana abstinence effects in marijuana smokers maintained in their environment. Arch Gen Psychiatry 58:917-924, 2001.
61Kouri, E.M.; Pope, H.G.; and Lukas, S.E. Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology 143:302-308, 1999.
62Steinberg, K.L.; Roffman, R.A.; Carroll, K.M.; Kabela, E.; Kadden, R.; Miller, M.; and Duresky, D. The Marijuana Treatment Project Research Group. Tailoring cannabis dependence treatment for a diverse population. Addiction 97(Suppl 1):135-142, 2002.
63Stephens, R.S.; Roffman R.A.; and Curtin, L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 68(5):898-908, 2000.
64Budney, A.J.; Higgins, S.T.; Radonovich, K.J.; and Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 68(6):1051-1061, 2000.
65Heyser, C.J.; Hampson, R.E.; and Deadwyler, S.A. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task-specific firing of hippocampal cells. Journal of Pharmacology & Experimental Therapeutics 264(1):294-307, 1993.
66Landfield, P.W.; Cadwallader, L.B.; and Vinsant, S. Quantitative changes in hippocampal structure following long exposure to delta-9-tetrahydrocannabinol: Possible mediation of glucocorticoid systems. Brain Res 443(1-2):47-62, 1988.
67Eldridge, J.C.; Murphy, L.L.; and Landfield, P.W. Cannabinoids and the hippocampal glucocorticoid receptor: recent findings and possible significance. Steroids 56:226-230, 1991.
68Landfield, P.W.; Waymire, J.C.; and Lynch, G. Hippocampal aging and adrenocorticoids: quantitative correlations. Science 202:1098-1101, 1978.
69Walker, M.J.; Huang, S.M.; Strangman, N.M.; Tsou, K.; and Sanudo-Pena, M.C. Pain modulation by the release of the endogenous cannabinoid anandamide. Proceedings of the National Academy of Sciences 96(21):12198-12203, 1999.
70Wenger, T.; Toth, B.E.; Juaneda, C.; Leonardelli, J.; and Tramu, G. The effects of cannabinoids on the regulation of reproduction. Life Sci 65(6-7):695-701, 1999.
71Lawston, J.; Borella, A.; Robinson, J.K.; and Whitaker-Azmitia, P.M. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55, 212-2. Brain Research 877:407-410, 2000.
72Chan, G.C.K.; Hinds, T.R.; Impey, S.; and Storm, D.R. Hippocampal neurotoxicity of delta-9-tetrahydrocannabinol. J Neuroscience 18(14):5322-5332, 1998.
73Piomelli, D.; Giuffrida, A.; Calignano, A.; and Rodriguez de Fonseca, F. The endocannabinoid system as a target for therapeutic drugs. TIPS 21:218-224, 2000.
